Method for recognizing and determining GnRH receptors and use of GnRH agonist for decreasing the replication of malignant cells bearing GnRH receptors of tumors orginating in the nervous system and/or meninges and/or of Kaposi sarcoma
OwnerJohannes C. J. van Groeningheninventor
Life of this patent
Estimating the term…
Abstract
A method for recognizing and determining GnRH receptors on abnormal cells of a tumor originating in the brain and/or nervous system and/or the meninges and/or on Kaposi sarcoma. Also, preparing diagnostic kits for tumors originating in the brain and/or nervous system and/or the meninges and/or for Kaposi sarcoma. Further, a method for decreasing cellular replication of GnRH-positive glioma, oat-cell carcinoma, malignant melanoma, or Kaposi sarcoma comprising administering to a cell or to a subject a replication decreasing amount of a GnRH agonist.
Claims14
A method for the detection and/or determination of GnRH receptors on tumor cells originating in brain and/or nervous system and/or the meninges and/or lungs and/or malignant melanoma and/or Kaposi sarcoma, said method comprising:
- contacting said cells with a ligand for a GnRH receptor;
- and
- determining if binding has occurred.
A method for the detection and/or determination of GnRH receptors on degenerate, cells of a tumor originating in brain and/or nervous system and/or the meninges, said method comprising:
- a) homogenizing peroperatively collected tumor tissue;
- b) separating the membrane fraction;
- c) determining the protein concentration in the membrane fraction of b);
- and
- d) determining the concentration of GnRH receptors in the membrane fraction of b) to diagnose the tumors.
A diagnostic kit for detecting GnRH receptor on tumor cells originating in brain and/or nervous system and/or the meninges and/or lungs and/or malignant melanoma and/or Kaposi sarcoma, said diagnostic kit comprising:
- a ligand for a GnRH receptor;
- and
- a means for detecting a bound ligand.
A method for decreasing cellular replication of GnRH-positive glioma, oat-cell carcinoma, malignant melanoma, or Kaposi sarcoma comprising:
- administering to a cell a replication decreasing amount of a GnRH agonist.
A method for decreasing cellular replication of GnRH-positive glioma, oat-cell carcinoma, malignant melanoma, or Kaposi sarcoma comprising:
- administering to a subject a replication decreasing amount of a GnRH agonist.
Dependencies are inferred from the claim text.